
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb's recent increases in probability of success (PoS) for key drug candidates, such as milvexian and the iber/mezi combination, signal a heightened confidence in their potential market performance, with risk-adjusted sales estimates rising substantially to $1.2 billion and $3.6 billion, respectively, for 2033. The company's robust pipeline and anticipated growth in products like Eliquis, alongside promising trends in their Growth Products, solidify a positive outlook on revenue prospects following guidance that exceeded market expectations. Additionally, strategic business development efforts and an emphasis on transforming its product portfolio contribute to a bullish sentiment regarding the company's long-term financial trajectory.
Bears say
Bristol-Myers Squibb's anticipated regulatory approval and launch delays for new products pose substantial risks to its revenue and earnings potential. Additionally, the company's forward EV/EBITDA multiple underperformance, at a level below the peer average of 11.2x, suggests that market confidence may be wavering. Compounding these concerns are the inherent risks associated with clinical trials, such as potential regulatory setbacks and competitive innovations that could diminish the relevance of new therapies.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares